为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向肝细胞癌中的肿瘤相关巨噬细胞：生物学、策略与免疫治疗
英文原题：Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy.
查看英文原题
Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肝细胞癌（HCC）是最具恶性的肿瘤之一，其特征是顽固的免疫抑制微环境。作为HCC肿瘤微环境（TME）的主要成员之一，肿瘤相关巨噬细胞（TAMs）在其发生和发展中发挥关键作用，包括刺激血管生成、增强免疫抑制以及促进耐药和癌症转移。本综述描述了TAMs的起源及表型异质性及其对HCC发生和发展的潜在影响，并讨论了可用于靶向TAMs的各种基于辅助治疗的策略。此外，我们重点介绍了基于免疫治疗的TAMs不同治疗模式，包括小分子抑制剂、免疫检查点抑制剂、抗体、肿瘤疫苗、过继细胞免疫治疗和用于药物递送的纳米载体，以探索新的联合疗法，并为临床改善HCC患者的预后和生活质量提供可行的治疗选择。
展开英文摘要原文
Hepatocellular carcinoma (HCC), one of the most malignant tumors, is characterized by its stubborn immunosuppressive microenvironment. As one of the main members of the tumor microenvironment (TME) of HCC, tumor-associated macrophages (TAMs) play a critical role in its occurrence and development, including stimulating angiogenesis, enhancing immunosuppression, and promoting the drug resistance and cancer metastasis.
This review describes the origin as well as phenotypic heterogeneity of TAMs and their potential effects on the occurrence and development of HCC and also discusses about various adjuvant therapy based strategies that can be used for targeting TAMs.
In addition, we have highlighted different treatment modalities for TAMs based on immunotherapy, including small molecular inhibitors, immune checkpoint inhibitors, antibodies, tumor vaccines, adoptive cellular immunotherapy, and nanocarriers for drug delivery, to explore novel combination therapies and provide feasible therapeutic options for clinically improving the prognosis and quality of life of HCC patients.
论文信息
- 作者
- Zheng H、Peng X、Yang S、Li X、Huang M、Wei S、Zhang S、He G
- 第一作者单位
- Department of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, 110032, China.China
- 通讯作者单位
- Department of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, 110032, China. sj_li_hangyu@sina.com.China
- 文献类型
- 综述
- 期刊
- Cell death discovery2023 Feb 15
- 原文标识
- PubMed 36792608 · DOI 10.1038/s41420-023-01356-7
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →